

# Medlab Clinical Ltd

13:29 29 Jun 2020

## Medlab Clinical completes first order of new hybrid cannabinoid to UK

Medlab Clinical Ltd (ASX:MDC) has completed the first order of its newly developed hybrid cannabinoid, Mg Optima Relax + CBD, which has been manufactured for Cultech Ltd in the UK.

In line with an exclusive UK/US distribution agreement of December 2019 to expand into the UK, the product has been manufactured and will be exported under licence to the UK.

The first order of 5,000 units is awaiting an 'ex-works' collection

Part of the agreement was the supply of a cannabinoid product combining Mg Optima Relax, a current Medlab nutraceuticals formulation available in Australian pharmacies and CBD that is used in the NanoCBD™ manufacture.

The product was developed in the USA and manufactured by American Nutritional Corp Inc.

After several months of development, the product has been manufactured in accordance to Cultech's requirements for 5,000 units.

### "First meaningful export for agreement"

Chief executive officer Sean Hall said: "This is our first meaningful export for this trade agreement and I see this as a start of great potential as we develop UK markets."

Magnesium (Mg) has well-known benefits for stress reduction, sleep, and mitigating restless legs.

Mg Optima Relax as a nutraceutical (that being with no CBD) is well placed in the Australian marketplace as a Medlab nutraceutical.

The combination of the two formulations (Mg Optima Relax and CBD) adds to the overall story of promoting relaxation and reducing stress.

Hall continued: "This product is not for Australia because of our laws relating to CBD use, but primed for other global legal markets.

"We would envisage a more global play regarding this product, as most Westerners are well versed in the benefits of magnesium, and hence its relatively easy to understand the synergistic benefits of combining magnesium and CBD."

Shares are up 7% to 15 cents.

**Price:** 0.325

**Market Cap:** \$90.89 m

### 1 Year Share Price Graph



### Share Information

**Code:** MDC

**Listing:** ASX

<b>52 week</b>	<b>High</b>	<b>Low</b>
	0.42	0.125

**Sector:** Cannabis

**Website:** [www.medlab.co](http://www.medlab.co)

### Company Synopsis:

Medlab Clinical Ltd (ASX:MDC) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).